Recent Updates
Recently added Catalysts

MINT1526A

Phase 1

Solid Cancers | Small molecule | Oncology |Roche Holding AG|Last Updated: Nov 2, 2016

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLED
Total Trials1
Total Enrollment54

FDA Designations

No designations recorded

Clinical trial landscape

MINT1526A · 1 trial · 1 indication

Phase 1 1
NCT01139723A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid TumorsSolid Cancers
COMPLETED54 Analytics
PHASE1COMPLETED
A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors
Solid Cancers
NCT0113972354
Unlock trial analytics

Study Endpoints

Primary Endpoints

Incidence and nature of dose-limiting toxicities (DLTs)
Days 1 to 21 of cycle 1
Incidence, nature, and severity of adverse events and serious adverse events, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v4.0
Day 1 to study completion

Secondary Endpoints

Pharmacokinetic parameters of MINT1526A (including total exposure, maximum and minimum serum concentration, clearance, volume of distribution at steady state)
Following administration of study drug
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
AEXPERIMENTAL -
BEXPERIMENTAL -

Interventions

NameTypeDescription
MINT1526ADRUGIntravenous escalating dose
bevacizumabDRUGIntravenous repeating dose
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites3

Inclusion Criteria: * Histologically or cytologically documented, incurable, or metastatic solid malignancy that has progressed on or failed to respond to regimens or therapies known to provide clinical benefit * Adequate hematologic and end organ function * Evaluable disease or measurable disease ...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about MINT1526A

What is MINT1526A used for?

MINT1526A is an investigational small molecule being studied for the treatment of solid cancers. It is administered intravenously, both as a single agent and in combination with bevacizumab, in patients with advanced solid tumors. The drug is currently in Phase 1 clinical development.

Who makes MINT1526A?

MINT1526A is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research on this investigational oncology drug for the treatment of solid cancers.

What phase is MINT1526A in?

MINT1526A is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for safety and pharmacokinetics in patients with advanced solid tumors.

What clinical trials is MINT1526A in?

MINT1526A has one completed clinical trial, NCT01139723, which studied the safety and pharmacokinetics of the drug administered intravenously as a single agent and in combination with bevacizumab in patients with advanced solid tumors. The trial enrolled 54 participants in the United States.

Is MINT1526A FDA approved?

MINT1526A is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for the treatment of solid cancers. The drug has completed one clinical trial, but it remains under investigation and has not been approved for commercial use.